-

IFF Pharma Solutions Launches Low Nitrite METHOCEL™ HPMC for Nitrosamine Mitigation

Low Nitrite METHOCEL™ HPMC reduces the potential for nitrosamine formation and provides consistent results in finished dosages.

NEW YORK--(BUSINESS WIRE)--IFF (NYSE: IFF) Pharma Solutions, a global leader in polymer innovations, today announced the launch of Low Nitrite METHOCEL™ hydroxypropyl methylcellulose (HPMC), a range of low nitrite cellulose ethers developed to reduce the risk of nitrosamine formation in finished pharmaceutical dosages. This innovative product line addresses the industry’s concern with nitrosamine risk and mitigation strategies for their formation. Through enhanced process controls and industry-leading analytical science, IFF Pharma Solutions limits and measures the level of nitrite in every batch of Low Nitrite METHOCEL™.

"METHOCEL HPMC is the polymer of choice for formulating both controlled release and immediate release pharmaceutical dosages," said Michael Baumann, global product manager, METHOCEL™, IFF Pharma Solutions. "Low Nitrite METHOCEL™ is designed to meet the highest standards of quality and safety. These specialized grades, which provide the same reliability and performance as standard METHOCEL™, help ensure minimal nitrite content, making them ideal for applications where low levels of nitrite are critical."

Effective in reducing nitrosamines in model formulations
Low Nitrite METHOCEL™ minimizes the potential of nitrosamine formation and helps ensure finished drug products comply with stringent safety regulations, enhancing the overall quality of our customers' drug products.

Designed to meet the highest standards of quality and safety
Using validated 2D ion chromatography with mass spectrometry, and with high selectivity and sensitivity, every batch receives a nitrite test result on the certificate of analysis. Each batch of Low Nitrite METHOCEL™ is tested to ensure nitrite levels are consistently at or below 200 parts per billion.

A dependable solution backed by polymer expertise
To ensure the best performance for our customers' drug products, Low Nitrite METHOCEL™ provides reliable and consistent results. This is supported by our polymer expertise and problem-solving mindset across the entire drug development pipeline.

For more information on Low Nitrite METHOCEL™, visit here.

Welcome to IFF
At IFF (NYSE: IFF), we make joy through science, creativity and heart. As the global leader in flavors, fragrances, food ingredients, health and biosciences, we deliver groundbreaking, sustainable innovations that elevate everyday products—advancing wellness, delighting the senses and enhancing the human experience. Learn more at iff.com, LinkedIn, Instagram and Facebook.

©2025 International Flavors & Fragrances Inc. (IFF). IFF, the IFF Logo, and all trademarks and service marks denoted with ™, SM or ® are owned by IFF or affiliates of IFF unless otherwise noted. All Rights Reserved.

Contacts

Emily Kaufman
Global Communications Specialist
+1 908.670.5691
emily.kaufman@iff.com

International Flavors & Fragrances

NYSE:IFF

Release Versions

Contacts

Emily Kaufman
Global Communications Specialist
+1 908.670.5691
emily.kaufman@iff.com

More News From International Flavors & Fragrances

IFF Launches PureStrong™, a Probiotic Made Specifically for Dogs

NEW YORK--(BUSINESS WIRE)--IFF (NYSE: IFF)—a global leader in flavors, fragrances, food ingredients and health & biosciences—is introducing PureStrong™, a new probiotic developed exclusively for canine digestive health. Today, many people consider their pet dogs part of the family. This shift is fueling rapid growth in the $3.2 billion U.S. pet supplement market. With nearly half of U.S. pet owners having purchased or considering probiotics for their dogs, PureStrong™ sets a new standard: p...

IFF Secures First Heart Health Claim for Soy Protein in Australia and New Zealand

ST. LOUIS--(BUSINESS WIRE)--IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients and health & biosciences announced today that a new heart health claim for isolated soy protein has been accepted by the Food Standards Australia New Zealand (FSANZ). The approval enables food and beverage manufacturers in Australia and New Zealand to link soy protein consumption with healthy blood cholesterol levels. “For decades, IFF has invested in the science behind soy protein and its...

IFF Expands Latin American Footprint With New Enzyme Hub, Brazil Application Lab

BUENOS AIRES, Argentina & SÃO PAULO--(BUSINESS WIRE)--IFF (NYSE: IFF) — a global leader in flavors, fragrances, food ingredients and health & biosciences — is enhancing regional production and innovation capabilities to better support the continued growth of its Health & Biosciences (H&B) business in Latin America, one of the fastest-growing markets for the company. The effort includes the transformation of the Arroyito site in Argentina into IFF’s first full fermentation‑based enzy...
Back to Newsroom